Amina Jindani
Professor Amina Jindani FRCP, is a leading clinical trialist, who has spent forty years conducting clinical trials seeking to improve the treatment of tuberculosis. She is Emeritus Professor of Tuberculosis Therapeutics at City St George's, University of London.[1]
Early life
Prof Jindani was born in Zanzibar in 1936, moved to the UK aged 15, and studied medicine at the University of London.[2] Her PhD focused on Early Bactericidal Assays - exploring the ability of tuberculosis drugs to clear bacilli from sputum.[3]
Clinical trials
Her randomised controlled trials have focussed on the treatment of drug-susceptible tuberculosis. They include Study A, RIFAQUIN, RIFATOX and RIFASHORT. Study A established the current six month standard treatment regimen, demonstrating that use of ethambutol (rather than rifamicin) during the 'continuation phase' resulted in inferior outcomes.[4] RIFAQUIN explored whether including high dose rifapentine and moxifloxacin in treatment regimens for drug susceptible tuberculosis might allow treatment to be shortened to four months - the shorter regimen was NOT found to be non-inferior to standard treatment.[5] RIFATOX described the effects of increasing the dose of rifampicin from 10 mg/kg to 15 or 20 mg/kg on key safety outcomes.[6] RIFASHORT found that four month treatment regimens using higher doses of rifampicin (up to 1800mg per day) were NOT non-inferior to the standard six month regimen.[7] Prof Jindani's collaborators included Denis Mitchison.
Recognition
Prof Jindani has been awarded the Ibn Sina Award for Medicine (2018), the Princess Chichibu Memorial Global TB Prize (2019) and was named City St George's Extraordinary Woman 2025.[8]
References
- ↑ "Professor Amina Jindani, City St George's profile page".
- ↑ "Professor Amina Jindani: the pioneering woman dedicated to eradicating tuberculosis". 19 March 2025.
- ↑ Amina Jindani (1980). "The early bactericidal activity of drugs in patients with pulmonary tuberculosis". The American Review of Respiratory Disease. 121 (6): 939–949. doi:10.1164/arrd.1980.121.6.939 (inactive 22 January 2026). PMID 6774638.
- ↑ Amina Jindani (2004). "Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial". Lancet (London, England). 364 (9441): 1244–1251. doi:10.1016/S0140-6736(04)17141-9. PMID 15464185.
- ↑ Amina Jindani (2014). "High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis". New England Journal of Medicine. 371 (17): 1599–1608. doi:10.1056/NEJMoa1314210. PMC 4233406. PMID 25337749.
- ↑ Amina Jindani (2016). "A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis". The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union Against Tuberculosis and Lung Disease. 20 (6): 832–838. doi:10.5588/ijtld.15.0577. PMID 27155189.
- ↑ Amina Jindani (2023). "Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis". NEJM Evidence. 2 (9). doi:10.1056/EVIDoa2300054. PMID 38320155 Check
|pmid=value (help). - ↑ "Professor Amina Jindani: the pioneering woman dedicated to eradicating tuberculosis". 19 March 2025.
This article "Amina Jindani" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Amina Jindani. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
